中国人群应用培美曲塞与多西他赛单药二线治疗晚期非小细胞肺癌的Meta分析

摘要

Objective It is to evaluate the clinical efficacy and safety of the pemetrexed compared with the docetaxel for treating advanced non-small-cell lung cancer( NSCLC)as second line therapy. Methods Such databases as PubMed,Elsevier Science Direct and CNKI were searched to collect the randomized controlled trials( RCTs)about pemetrexed versus docetaxel for the treatment of NSCLC as second therapy. RevMan 5. 0 soft ware was used for Meta-analyses. Results Seven studies invol-ving 803 patients were included. The results of Meta-analyses showed that,in the aspect of efficacy,there was no significant difference between the two groups in the effective rate,the disease control rate,and the one-year survival rate;in the aspect of safety,compared with docetaxel,pemetrexed could reduce the neutropenia and the alopecia,increase rash. There was no sig-nificant difference in hemoglobin,thrombocytopenia,nausea and vomiting,diarrhea and fatigue between two groups. Conclu-sion Pemetrexed has similar efficacy to docetaxel for advanced NSCLC patients,but it has fewer side effects of neutropenia and alopecia.%目的：比较中国人群应用培美曲塞与多西他赛单药二线治疗晚期非小细胞肺癌的疗效和安全性。方法计算机检索 PubMed、Elsevier Science Direct、CNKI等数据库，收集中国人群应用培美曲塞与多西他赛单药二线治疗晚期肺非小细胞肺癌的随机对照试验，用Cochrane协作网提供的Revman 5.0软件对数据进行Meta分析。结果共纳入7个研究，803例患者，Meta分析结果显示：在疗效方面，2组的有效率、疾病控制率、1年生存率等比较差异无统计学意义。在安全性方面，与多西他赛组相比，培美曲塞组重度中性粒细胞计数下降、脱发发生率低，皮疹发生率高；血红蛋白下降、血小板计数下降、恶心、呕吐、腹泻、乏力等发生率2组比较差异无统计学意义。结论多西他赛与培美曲塞单药二线治疗晚期非小细胞肺癌疗效相似，但培美曲塞中性粒细胞计数下降、脱发反应较轻。